Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
Harefuah|October 1, 1996
[Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs]S Abu-Abid, M Gutman, D Lev, et al.
Acta Obstetricia Et Gynecologica Scandinavica|July 1, 1993
A second thought on second look laparotomyA Bar-Am, F Kovner, J B Lessing, et al.
Oncology|January 11, 2001
Is forequarter amputation justified for palliation of intractable cancer symptoms?O Merimsky, Y Kollender, M Inbar, et al.
Annals of Surgical Oncology|April 13, 2000
Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerationsJ Issakov, O Merimsky, M Gutman, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II studyO Merimsky, I Meller, G Flusser, et al.
Journal of Neuro-Oncology|June 9, 1999
Radiation therapy of metastatic spinal cord compression. Multidisciplinary team diagnosis and treatmentF Kovner, S Spigel, I Rider, et al.
Journal of the National Cancer Institute|July 17, 1998
Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumorsW H Gotlieb, E Friedman, R B Bar-Sade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Risk of colorectal neoplasia associated with the adenomatous polyposis coli E1317Q variantM J Hall, E Liberman, O Dulkart, et al.
Bone Marrow Transplantation|April 15, 2003
Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patientsS M Stemmer, I Hardan, H Raz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerM E R O'Brien, N Wigler, M Inbar, et al.
Pageof 23